Latest Articlesddd
Regenxbio Results from RGX-121 for MPSII Regenxbio (RGNX) announced interim data from Phase I/II trial of …
Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, …
From Amarin Amarin (AMRN) announced the U.S. FDA has approved a new indication and label expansion for …
Exelixis Positive Results from IMspire 150 Exelixis (EXEL) announced positive results from IMspire 150; the phase 3 …
Ionis Pharmaceuticals
Ionis Pharmaceuticals (IONS) announces a private placement of $507.5 million principal amount of 0.125% convertible …
Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at …
Gilead’s CAR-T Product Yescarta Results Kite, a Gilead (GILD) subsidiary, announced new data from the ZUMA-1 trial …
Firstly, Forty-Seven and IVERIC bio We remind that the two condemned stocks Forty-Seven (FTSV) and IVERIC bio …
The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, …
Novartis to Acquire The Medicines Company Novartis (NVS) decided to buy The Medicines Company (MDCO) at …
Prohost Letter #437 An All Time High Market More Prohost Picks Have Reached the 2019 Targets …
Alnylam Granted FDA Early Approval of GIVLAARI™ for AHP Alnylam’s (ALNY) stock outperformed as its subcutaneous …
Vertex Pharmaceuticals and CRISPR Therapeutics Rallied Today Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced positive, interim …
PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics (PTCT) has positive results from part 2 of …
Reata Pharmaceuticals CARDINAL Study Met Primary and Key Secondary Endpoints Reata Pharmaceuticals (RETA) announced that the …
Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX® From Exelixis (EXEL) we learned that its …
FDA Approval for Celgene and Acceleron Drug REBLOZYL® The U.S. Food and Drug Administration (FDA) has …
The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” …
Exelixis and Daiichi Sankyo Partner to Prevent and Treat Diabetic Nephropathy Exelixis (EXEL) and Daiichi Sankyo …
Halozyme Therapeutics is Focusing on ENHANZE® Technology Halozyme Therapeutics (HALO) decides to focus on its ENHANZE® …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
